Nimble Therapeutics and Swedish company Svar Life Science are collaborating to discover, develop and commercialize diagnostic tests based on Nimble’s novel biomarker discovery engine, the company announced today.

“We are excited to partner with a leading, well-respected life science company like Svar,” Nimble Therapeutics CEO Jigar Patel said in a statement. “This collaboration combines the strengths of our two organizations to potentially bring new and improved tests to patients with autoimmune disorders.”

According to a release, the collaboration initially will leverage a novel panel of rheumatoid arthritis biomarkers discovered using Nimble’s comprehensive human proteome immunoprofiling.

Nimble will receive an undisclosed upfront payment and will be eligible for downstream milestone payments and royalties on product sales.